Predicting 10-year survival after resection of colorectal liver metastases; an international study including biomarkers and perioperative treatment
- PMID: 35430383
- PMCID: PMC9117473
- DOI: 10.1016/j.ejca.2022.01.012
Predicting 10-year survival after resection of colorectal liver metastases; an international study including biomarkers and perioperative treatment
Abstract
Background: The aim of this study was to develop a prediction model for 10-year overall survival (OS) after resection of colorectal liver metastasis (CRLM) based on patient, tumour and treatment characteristics.
Methods: Consecutive patients after complete resection of CRLM were included from two centres (1992-2019). A prediction model providing 10-year OS probabilities was developed using Cox regression analysis, including KRAS, BRAF and histopathological growth patterns. Discrimination and calibration were assessed using cross-validation. A web-based calculator was built to predict individual 10-year OS probabilities.
Results: A total of 4112 patients were included. The estimated 10-year OS was 30% (95% CI 29-32). Fifteen patient, tumour and treatment characteristics were independent prognostic factors for 10-year OS; age, gender, location and nodal status of the primary tumour, disease-free interval, number and diameter of CRLM, preoperative CEA, resection margin, extrahepatic disease, KRAS and BRAF mutation status, histopathological growth patterns, perioperative systemic chemotherapy and hepatic arterial infusion pump chemotherapy. The discrimination at 10-years was 0.73 for both centres. A simplified risk score identified four risk groups with a 10-year OS of 57%, 38%, 24%, and 12%.
Conclusions: Ten-year OS after resection of CRLM is best predicted with a model including 15 patient, tumour, and treatment characteristics. The web-based calculator can be used to inform patients. This model serves as a benchmark to determine the prognostic value of novel biomarkers.
Keywords: Biomarkers; Colorectal liver metastases; Prediction; Prognostic factors.
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Conflict of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr Groot Koerkamp received pumps for intra-arterial chemotherapy for use in clinical trials from Tricumed.
Figures


Comment in
-
Letter re: Predicting 10-year survival after resection of colorectal liver metastases: an international study including biomarkers and perioperative treatment: Several additional analysis methods.Eur J Cancer. 2023 Mar;182:98-99. doi: 10.1016/j.ejca.2023.01.008. Epub 2023 Jan 18. Eur J Cancer. 2023. PMID: 36758477 No abstract available.
References
-
- Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007;25(29):4575–80. - PubMed
-
- Cucchetti A, Ferrero A, Cescon M, Donadon M, Russolillo N, Ercolani G, et al. Cure model survival analysis after hepatic resection for colorectal liver metastases. Annals of surgical oncology. 2015;22(6):1908–14. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous